GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regentis Biomaterials Corp (NAS:RGNT) » Definitions » Beta

Regentis Biomaterials (Regentis Biomaterials) Beta : N/A (As of Jun. 17, 2024)


View and export this data going back to 2050. Start your Free Trial

What is Regentis Biomaterials Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-17), Regentis Biomaterials's Beta is Not available.


Regentis Biomaterials Beta Historical Data

The historical data trend for Regentis Biomaterials's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regentis Biomaterials Beta Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22
Beta
- - -

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Beta Get a 7-Day Free Trial - - - - -

Competitive Comparison of Regentis Biomaterials's Beta

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regentis Biomaterials's Beta Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's Beta distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's Beta falls into.



Regentis Biomaterials Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Regentis Biomaterials  (NAS:RGNT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Regentis Biomaterials Beta Related Terms

Thank you for viewing the detailed overview of Regentis Biomaterials's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Regentis Biomaterials (Regentis Biomaterials) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12 Ha’ilan Street, P.O. Box 260, Northern Industrial Zone, Or-Akiva, ISR, 306000
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Regentis Biomaterials (Regentis Biomaterials) Headlines

No Headlines